Lantheus Holdings, Inc. (NASDAQ:LNTH) had its price target hoisted by analysts at Credit Suisse Group from $19.00 to $23.00 in a report issued on Friday. The firm currently has a “neutral” rating on the medical equipment provider’s stock. Credit Suisse Group’s price target indicates a potential upside of 3.14% from the stock’s current price.
LNTH has been the subject of a number of other research reports. Wells Fargo & Company raised Lantheus Holdings from a “market perform” rating to an “outperform” rating in a report on Thursday. Jefferies Group LLC reissued a “buy” rating and issued a $22.00 target price (up previously from $18.00) on shares of Lantheus Holdings in a report on Wednesday, August 2nd. Cantor Fitzgerald started coverage on Lantheus Holdings in a report on Monday, July 17th. They issued an “overweight” rating and a $22.00 target price for the company. Zacks Investment Research raised Lantheus Holdings from a “hold” rating to a “strong-buy” rating and set a $18.00 target price for the company in a report on Thursday, August 3rd. Finally, BidaskClub lowered Lantheus Holdings from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 17th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Lantheus Holdings has an average rating of “Buy” and a consensus price target of $20.40.
Lantheus Holdings (LNTH) traded down $0.30 during trading on Friday, hitting $22.30. The company’s stock had a trading volume of 863,350 shares, compared to its average volume of 389,281. The company has a market cap of $836.38, a price-to-earnings ratio of 19.91, a price-to-earnings-growth ratio of 1.63 and a beta of 0.92. Lantheus Holdings has a twelve month low of $7.95 and a twelve month high of $23.00. The company has a current ratio of 2.92, a quick ratio of 2.43 and a debt-to-equity ratio of -3.05.
Lantheus Holdings (NASDAQ:LNTH) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported $0.24 EPS for the quarter, topping the Zacks’ consensus estimate of $0.20 by $0.04. The business had revenue of $79.94 million during the quarter, compared to analyst estimates of $77.18 million. Lantheus Holdings had a negative return on equity of 44.05% and a net margin of 9.59%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.15 EPS. research analysts expect that Lantheus Holdings will post 1.1 earnings per share for the current fiscal year.
In related news, Director David F. Burgstahler sold 140,846 shares of Lantheus Holdings stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $17.27, for a total value of $2,432,410.42. Following the completion of the sale, the director now owns 13,248 shares of the company’s stock, valued at $228,792.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David F. Burgstahler sold 6,000 shares of Lantheus Holdings stock in a transaction on Friday, September 1st. The stock was sold at an average price of $17.10, for a total value of $102,600.00. Following the completion of the sale, the director now directly owns 13,248 shares of the company’s stock, valued at approximately $226,540.80. The disclosure for this sale can be found here. Insiders sold 903,099 shares of company stock valued at $15,443,485 in the last ninety days. 2.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Royce & Associates LP bought a new stake in shares of Lantheus Holdings in the second quarter worth $4,896,000. QS Investors LLC purchased a new position in Lantheus Holdings during the second quarter valued at $2,256,000. Bank of New York Mellon Corp lifted its position in Lantheus Holdings by 6.3% during the first quarter. Bank of New York Mellon Corp now owns 68,473 shares of the medical equipment provider’s stock valued at $856,000 after purchasing an additional 4,084 shares in the last quarter. Thrivent Financial For Lutherans purchased a new position in Lantheus Holdings during the second quarter valued at $321,000. Finally, Prudential Financial Inc. purchased a new position in Lantheus Holdings during the second quarter valued at $835,000. 85.03% of the stock is owned by institutional investors.
About Lantheus Holdings
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
What are top analysts saying about Lantheus Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Lantheus Holdings Inc. and related companies.